Avidity Biosciences Inc RNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/18/24 EDT
23.04quote price arrow down-0.51 (-2.17%)
Volume
1,117,309
52 week range
4.82 - 27.66
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close23.04
  • 52 Week High27.66
  • 52 Week High Date04/03/24
  • 52 Week Low4.82
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap2.188B
  • Shares Out94.94M
  • 10 Day Average Volume0.95M
  • Dividend-
  • Dividend Yield-
  • Beta0.80
  • YTD % Change154.59

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close23.04
  • 52 Week High27.66
  • 52 Week High Date04/03/24
  • 52 Week Low4.82
  • 52 Week Low Date10/31/23
  • Market Cap2.188B
  • Shares Out94.94M
  • 10 Day Average Volume0.95M
  • Dividend-
  • Dividend Yield-
  • Beta0.80
  • YTD % Change154.59

RATIOS/PROFITABILITY

  • EPS (TTM)-2.90
  • P/E (TTM)-7.93
  • Fwd P/E (NTM)-7.22
  • EBITDA (TTM)-233.454M
  • ROE (TTM)-39.34%
  • Revenue (TTM)9.56M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,219.88%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Avidity Biosciences Inc

 

Profile

MORE
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical...
Troy Wilson J.D., Ph.D.
Chairman of the Board
Sarah Boyce
President, Chief Executive Officer, Director
Michael Maclean
Chief Financial and Chief Business Officer
W. Michael Flanagan Ph.D.
Chief Scientific and Technical Officer
Address
10578 SCIENCE CENTER DRIVE, SUITE 125
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
DYN
Dyne Therapeutics Inc
23.65-1.17-4.71%
KURA
Kura Oncology Inc
17.68-0.31-1.72%
CLDX
Celldex Therapeutics Inc
38.53-1.10-2.78%
RCKT
Rocket Pharmaceuticals Inc
23.48-0.20-0.84%
NTLA
Intellia Therapeutics Inc
21.32-0.18-0.84%